SCHEMBL6638484

SCHEMBL6638484

NC(=O)C=Cc1ccc(O)c(C=O)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PELI1 Q96FA3 4/20 0.68
ERN1 O75460 7/20 0.49
KDM4E B2RXH2 2/20 0.47
HSD17B10 Q99714 2/20 0.47
MAPT P10636 2/20 0.47
BACE1 P56817 2/20 0.47
TTR P02766 2/20 0.47
APP P05067 2/20 0.47
MEN1 O00255 1/20 0.47
HDAC3 O15379 1/20 0.47
CA12 O43570 1/20 0.47
AKR1B10 O60218 1/20 0.47
ALDH1A1 P00352 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
LMNA P02545 1/20 0.47
MMP1 P03956 1/20 0.47
GLA P06280 1/20 0.47
POLB P06746 1/20 0.47
CA3 P07451 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6640901 0.84 KDM4E (0.68) PELI1ERN1KDM4EHSD17B10MAPT
SCHEMBL6644081 0.84 KDM4E (0.68) PELI1ERN1KDM4EHSD17B10MAPT
SCHEMBL19454449 0.83 BACE1 (0.62) KDM4EHSD17B10MAPTBACE1APP
SCHEMBL1314851 0.82 KDM4E (0.69) PELI1KDM4EHSD17B10MAPTBACE1
SCHEMBL8916399 0.82 KDM4E (0.69) PELI1KDM4EHSD17B10MAPTBACE1
SCHEMBL29773361 0.82 KDM4E (0.69) PELI1KDM4EHSD17B10MAPTBACE1
SCHEMBL6639041 0.79 PELI1 (0.70) PELI1TTRAPPMMP1MMP2
SCHEMBL25705683 0.79 BACE1 (0.58) PELI1ERN1KDM4EHSD17B10MAPT
SCHEMBL14281152 0.78 ERN1 (0.52) ERN1KDM4E
SCHEMBL23895047 0.78 BACE1 (0.73) KDM4EHSD17B10MAPTBACE1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1412327-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG Biomedical Institute (US) 2004-04-28 EP claimed
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-11-06 US claimed
WO-2002096867-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG BIOMEDICAL INSTITUTE (US) 2002-12-05 WO claimed
EP-1412327-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG Biomedical Institute (US) 2004-04-28 EP disclosed
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-11-06 US disclosed
US-20030187007-A1 Inhibitors of protein kinase for the treatment of disease LG BIOMEDICAL INSTITUTE 2003-10-02 US disclosed
WO-2002096867-A2 INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE LG BIOMEDICAL INSTITUTE (US) 2002-12-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030208067-A1 Inhibitors of protein kinase for the treatment of disease MAP3K20, MAP3K1, MAP3K2 PELI1 1219/4885ERN1 446/4885KDM4E 1458/4885
US-20030187007-A1 Inhibitors of protein kinase for the treatment of disease MAP3K20, MAP3K1, MAP3K2 PELI1 1219/4885ERN1 446/4885KDM4E 1458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.